Maidstone Hospital

Maidstone ME16 9QQ

3 studies enrolling now · 10 studies all time

What they study most

Anaplastic Lymphoma Kinase-positive, Chronic Lymphocytic Leukemia, Colorectal Cancer, Colorectal Cancer (CRC), Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer, Leukemia, Locally Advanced or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Non-small Cell Lung Cancer, Small Lymphocytic Lymphoma

Studies at this site

• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation — Recruiting now
• Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC — Recruiting now
• A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Recruiting now
• Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation — Completed
• A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) — Running, not enrolling
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) — Running, not enrolling
• A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer — Stopped early
• A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer — Completed
• A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy — Completed